Key insights
- Twist Bioscience (TWST) reached a 52-week high, driven by strong revenue growth and positive analyst ratings, despite an EPS miss. Analysts at TD Cowen and Leerink raised price targets, reflecting confidence in the company's long-term revenue projections. While the stock is trading above its fair value, indicating potential overvaluation, the overall sentiment remains bullish due to strategic advancements and market performance.
Twist Bioscience Corp (TWST) stock reached a 52-week high, trading at $66.84, marking a significant milestone for the company. Over the past year, the stock has seen an impressive increase of 121%, reflecting strong investor confidence and positive market conditions. The biotechnology company’s market capitalization now stands at $4.06 billion, with year-to-date returns exceeding 104%. This surge in stock price is indicative of the company’s robust performance and strategic advancements in the biotechnology sector. The 52-week high highlights the upward momentum Twist Bioscience has experienced, positioning the company favorably within the market landscape. According to InvestingPro analysis, the stock is currently trading above its Fair Value, placing it among overvalued stocks in the market. Investors seeking deeper insights can access one of 13+ additional InvestingPro Tips, along with comprehensive Pro Research Reports covering TWST and 1,400+ other US equities.
In other recent news, Twist Bioscience reported its second-quarter fiscal year 2026 earnings, highlighting strong revenue growth but with a notable earnings per share (EPS) miss. The company achieved total revenues of $111 million, marking a 19% increase year-over-year and surpassing the consensus estimate of $108 million. However, the EPS came in at -$0.71, which was below the forecasted -$0.48. Despite the earnings miss, investor sentiment remained positive, as reflected in the stock’s pre-market performance.
Additionally, TD Cowen raised its price target for Twist Bioscience to $68 from $58, maintaining a Buy rating, citing the revenue beat as a key factor. Leerink also increased its price target on the stock to $80 from $70, sustaining an Outperform rating. This adjustment followed the company’s Investor Day, where management projected revenue to reach approximately $1 billion by fiscal year 2031, indicating a compound annual growth rate of over 16%. These developments underscore the company’s growth prospects and the confidence of analyst firms in its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for TWST plus thousands of other stocks and find your next hidden gem with massive upside.